Clinical and Experimental Dermatology

Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology

Retrieved on: 
Wednesday, September 27, 2023

GREENVILLE, SC, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Z-pod® topical delivery platform was used in various in vivo studies that were highlighted in a peer-reviewed paper just published online by Experimental Dermatology titled, “Nano-encapsulated anandamide (AEA) reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus [CLE].”

Key Points: 
  • His colleagues at George Washington University (GWU) and AECOM wrote the paper, designed the studies, and performed some of the studies.
  • Approximately 500,000 people in the U.S. suffer from cutaneous lupus erythematosus (CLE), with a significant impact on quality of life.
  • Moreover, the technology enables the use of a novel active ingredient that otherwise would not be an effective tool in managing this disease.
  • The principal investigator of the grant-work is Zylö’s A. Draganski, and the primary collaborator is Dr. Werth.

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023

WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.
  • John Koconis, Chairman and Chief Executive Officer of Timber, commented, “The development of our lead asset, TMB-001, continued to progress on several fronts during the first quarter of 2023.
  • For the first quarter ended March 31, 2023, Timber recorded no revenue compared to revenue of $83,177 in the first quarter of 2022.
  • For Timber’s complete financial results for the first quarter ended March 31, 2023, see the Company’s Quarterly Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023.

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

Retrieved on: 
Friday, March 31, 2023

WARREN, NJ, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • John Koconis, Chairman and Chief Executive Officer of Timber, commented, “Timber had an exciting year in 2022 and achieved several significant milestones.
  • These designations, combined with the positive Phase 2b results, are assisting in our Phase 3 ASCEND clinical trial recruitment, which has now reached 50%.
  • In Spring 2022, Timber received Breakthrough Therapy designation and Fast Track designation from the FDA for TMB-001.
  • For Timber’s complete financial results for the fourth quarter and year ended December 31, 2022, see the Company’s Annual Form 10-K filed with the Securities and Exchange Commission on March 31, 2023.

Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology

Retrieved on: 
Monday, March 20, 2023

BASKING RIDGE, NJ, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the online publication of a sub-analysis of the Phase 2b CONTROL study in Clinical and Experimental Dermatology (CED), the educational journal of the British Association of Dermatologists. The CONTROL study evaluated TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, in subjects nine years of age and older with moderate to severe congenital ichthyosis (CI).

Key Points: 
  • The CONTROL study evaluated TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, in subjects nine years of age and older with moderate to severe congenital ichthyosis (CI).
  • CI is a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin.
  • “In this sub-analysis, participants in the CONTROL study with ARCI and XLRI mostly showed comparable percentage differences in responses to treatment with a novel topical isotretinoin formulation versus vehicle.
  • The intent-to-treat (ITT) population consisted of all randomized participants who received one or more doses of the study medication.